Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. - Wikidata - awgldk - TriplyDB

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

http://www.wikidata.org/entity/Q37801220

about

The Crossroads of Geriatric Cardiology and Cardio-Oncology Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review Cardiac effects of anticancer therapy in the elderly Evaluation and management of patients with heart disease and cancer: cardio-oncology Optimal management of breast cancer in the elderly patient: current perspectives Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Treatment of soft tissue sarcoma: a focus on earlier stages.Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis.Metabolic syndrome in Mexican women survivors of breast cancer: a pilot study at a general hospital.Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer.Current targeted therapies in breast cancer: clinical applications in the elderly woman.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly.Reconsideration of key articles regarding medication-related problems in older adults from 2011.Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography.Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity.Senior adult oncology.Lipid nature and their influence on opening of redox-active liposomes.Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.Evidence-based risk assessment and recommendations for physical activity clearance: Consensus Document 2011.Treatment of the elderly patient with diffuse large B cell lymphoma.Treatment of metastatic breast cancer in women aged 65 years and older.Triple-negative breast cancer in the older population.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.An update on adjuvant systemic therapy for elderly patients with early breast cancer.Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes.Illuminating anthracycline cardiotoxicity: the renaissance of evidence-based onco-cardiology.Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 s

P2860

Q26778666-228069B6-3C4C-422F-B6EE-815173EFD8AB Q26785496-52E21BFC-35C9-42F4-8968-1992F10E524C Q26850736-9A75387C-9850-47EC-B9F6-A259DF235184 Q26863244-C8AAB096-A0F5-450F-ACC4-A461BB5562CC Q26998273-6186CEB1-0696-4C00-98A9-74028EB7541B Q27690879-77F5014E-DE03-4928-9CB4-27914D3EF4D8 Q28070311-D8D58ABD-C933-4764-A823-4A163E049C88 Q30240235-43A7F177-02B6-41EF-B831-0E7279282054 Q31120288-14DDF8CF-568C-4955-B1F6-3B8A5184DD21 Q34745890-AC9B105F-BB8E-400E-96F2-422D159FE7BF Q35030104-F4248992-64BF-457B-92DF-F27E592D20F3 Q35125211-82460B18-6148-4968-A434-30AF80DBD5BA Q35584741-89457BA2-9067-4218-98D8-05AC50845BE5 Q35673260-F91B4080-917C-4895-AED4-C06A161C4BC9 Q35716026-779BD129-F4F2-47FF-A5AB-DBEFC2FF26A1 Q36043785-54491C9F-9BBA-4452-B60B-4F2C4BB87B68 Q36650772-626A1E76-3961-466A-AD6A-F8C8B9EAB0BD Q36804526-F8DA64BC-13C9-43F2-97A6-42169DF38DE6 Q36825438-3C27ECDA-5001-4290-B099-8B12B0EFAF52 Q36851424-7EA08902-914A-4B02-83D9-8561E72327E8 Q37186746-1AB597BC-84C0-4CBF-86EF-C212EB564D7A Q37570641-3BF74040-E0C6-4285-BB7C-4CC748DA205F Q37719598-02BDF498-FF30-4B3B-ACD3-27183EE764C3 Q37908100-6B189106-FE0A-4F9A-B3ED-545CB06B8BDF Q37998553-A6F954BD-4F0C-47C7-A681-7A455ABD6B8F Q38023511-EFBB7E2C-9A43-4595-9C4F-64D933C397AD Q38046584-EF1A6752-E665-4BDF-9FBE-8CF521501273 Q38110232-F61F55AA-AF89-44D6-AFED-2169C156D407 Q38165751-D98F0AA9-7AF7-4712-9FA6-7693FE238396 Q38190105-7F3D69DE-5B2E-4F35-8DE2-0AE771427757 Q38368230-4D9017A5-ED01-4A2B-8FBF-6A079E7C4810 Q38787215-E2F3BF6B-0A7B-48FB-9D2A-35F7E4841729 Q38931502-0EBC1A51-546B-469D-BCBA-7F4CC6380E50 Q39742304-0900242A-1F08-4574-A661-905C25D4DE25 Q40980827-30E9DACC-E12F-4DBB-9FC2-D0EC1483CC34 Q41928716-7E321A2E-1FB8-443D-A628-93B348DD628F Q42080818-00969E07-C54D-4E8A-B347-ACBDAA327984 Q42216535-A2818EDC-746D-4FF6-AF0C-E6F0FF28512A Q45180255-006EA399-9A94-4182-AFED-1388F66BF275 Q47892546-DB3696E1-7EC0-4E7E-9452-288F7D8ED86B

P2860

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

http://www.wikidata.org/entity/Q37801220

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@en

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@nl

type

label

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@en

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@nl

prefLabel

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@en

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

@nl

P1433

Q37801220-BE59BC09-EB7B-4124-92DB-022D9F288B13

P1476

Q37801220-52AF7CE3-D555-4501-82A4-D8A92AF18D6C

P2093

Q37801220-021FB8F9-EF14-480F-876A-C31A7FABB472

Q37801220-3D7D88CA-CBFB-4286-8B92-09E457157D62

Q37801220-5751D7F6-472A-4F3F-A8D6-835EC1EF1215

Q37801220-5D92E0E7-88CD-4FC7-9254-EB2A0AE93101

Q37801220-6CE37197-CED9-4C04-A027-2FAFD6CB911C

Q37801220-9D87D17E-E17A-4F40-B95A-476CF09595A8

Q37801220-AD3A0C78-DE12-4857-8FA5-2198D0F7665F

Q37801220-B97E66B4-6F5D-45BF-A65D-2BF7DCD4BEFB

Q37801220-E6C52A60-CE7A-48F5-B277-B5C3828B22DE

P2860

Q37801220-00154F9C-9265-4ADA-B651-76BC37D4BC8C

Q37801220-018F94D5-DBD7-4DB0-ACEC-DF0D742D1A6C

Q37801220-054FF989-410B-4D71-82BC-7844B9350A35

Q37801220-072E64BE-A4E7-4E19-B547-87184E6AAF27

Q37801220-08F959A1-E2A2-4A79-97A2-ABD6908444A0

Q37801220-0DFE9DA2-023F-4CB3-B166-335A694E4D51

Q37801220-1B2BA9EF-8B87-4618-BE1D-5343958189A0

Q37801220-2271E63F-F2DD-4C38-AFEB-FCBFD19F14EE

Q37801220-3126F6E6-B457-446A-A998-FB15636DCD67

Q37801220-3502D6A0-A6C8-4E9C-A1F1-571F1B8E3698

P304

Q37801220-27E43F76-373E-4D5C-91D7-EA86A72C8018

P31

Q37801220-64DEC796-9C2D-4DF3-8961-57A4879A6140

P356

Q37801220-2C36602E-681B-46EA-AC51-C413449987C7

P433

Q37801220-C77D74A5-8688-4C9F-9E17-BE5E815A4F02

P478

Q37801220-DEF86D98-AD94-438D-BEDF-7A14D8DD3D3D

P50

Q37801220-11A03E8D-4934-45D7-B91F-F54BEB201B89

Q37801220-5B9149B6-6B54-4CF8-9A8B-D4CB55AF93F3

Q37801220-E6EF888C-9813-4F77-9378-4559943B3417

P577

Q37801220-9CDC1E6D-A259-41A9-B152-66DB9AA8D5D5

P5875

Q37801220-7AAD2861-E8A7-463A-BF55-7B13E4B1324F

P698

Q37801220-6D9ACA2B-AC99-46D7-9ADB-A37223196CC6

P921

Q37801220-FAD99F3A-7A1A-4298-A555-C0F8D7BD77E9

P356

P1433

Annals of Oncology

P1476

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

@en

P2093

C Bernard-Marty

http://www.w3.org/2001/XMLSchema#string

E G C Brain

http://www.w3.org/2001/XMLSchema#string

F Erdkamp

http://www.w3.org/2001/XMLSchema#string

G Batist

http://www.w3.org/2001/XMLSchema#string

K Krzemieniecki

http://www.w3.org/2001/XMLSchema#string

M Aapro

http://www.w3.org/2001/XMLSchema#string

M Ryberg

http://www.w3.org/2001/XMLSchema#string

R Leonard

http://www.w3.org/2001/XMLSchema#string

U Wedding

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Risk factors for doxorubicin-induced congestive heart failure

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ609

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Silvio Monfardini

Pierre-Louis Soubeyran

P577

2010-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47459580

http://www.w3.org/2001/XMLSchema#string

P698

20956616

http://www.w3.org/2001/XMLSchema#string

P921